STRASBOURG, France--(BUSINESS WIRE)--Regulatory News:
Transgene (Paris:TNG) today announced that management will give a corporate presentation at the upcoming Ladenburg Thalmann 2015 Healthcare Conference for investors to be held September 29, 2015 in New York, NY. The presentation will be at 1 PM ET.
A live webcast, as well as replay, will be available on the Company’s website at www.transgene.fr in the Investor Relations/Investor Events & Presentations section.
About Transgene
Transgene S.A. (Euronext: TNG), part of Institut Mérieux, is a publicly traded French biopharmaceutical company focused on discovering, developing and manufacturing targeted immunotherapies for the treatment of cancer and infectious diseases. Transgene’s programs utilize viral vector technology with the goal of indirectly or directly killing infected or cancerous cells. The Company’s two lead clinical-stage programs are: TG4010 for non-small cell lung cancer and Pexa-Vec for liver cancer. The Company has several other programs in clinical and pre-clinical development. Transgene is based in Strasbourg, France, and has additional operations in Lyon, as well as satellite offices in China and the U.S. Additional information about Transgene is available at www.transgene.fr.
Contacts
Transgene
Elisabetta Castelli, +33 (0)3 88 27 91 21
Director IR
Laurie Doyle, +1 (339) 832 0752
Director IR US & Corporate Communications
investorrelations@transgene.fr
or
MC Services
Raimund Gabriel? +49 89 210 228 30
raimund.gabriel@mc-services.eu
Shaun Brown? +44 207 148 5998
shaun.brown@mc-services.eu
Help employers find you! Check out all the jobs and post your resume.
